PARIS--(BUSINESS WIRE)--Regulatory News: ExonHit Therapeutics (Paris:ALEHT) today reported the signing by Allergan, Inc. (NYSE: AGN) and Bristol-Myers Squibb Company (NYSE: BMY) of a global exclusive license agreement for the development and commercialization of EHT/AGN 0001 (AGN-209323), ExonHit’s lead compound from the most advanced program of its collaboration with Allergan. EHT/AGN 0001 is a Phase II-ready, orally bio-available small molecule in clinical development for neuropathic pain. This agreement between Allergan and Bristol-Myers Squibb also encompasses EHT/AGN 0002 and associated back-up compounds.
